SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species

• Published in: eLife 2022-05, Vol.11
• Main Authors: Demange, Pascal, Joly, Etienne, Marcoux, Julien, Zanon, Patrick R A, Listunov, Dymytrii, Rullière, Pauline, Barthes, Cécile, Noirot, Céline, Izquierdo, Jean-Baptiste, Rozié, Alexandrine, Pradines, Karen, Hee, Romain, de Brito, Maria Vieira, Marcellin, Marlène, Serre, Remy-Felix, Bouchez, Olivier, Burlet-Schiltz, Odile, Oliveira, Maria Conceição Ferreira, Ballereau, Stéphanie, Bernardes-Génisson, Vania, Maraval, Valérie, Calsou, Patrick, Hacker, Stephan M, Génisson, Yves, Chauvin, Remi, Britton, Sébastien
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis; Biochemistry; Biochemistry and Chemical Biology; Biochemistry, Molecular Biology; Cell death; Cell membranes; chiral cytototoxic lipid; Cloning; CRISPR; Cytotoxicity; Endoplasmic reticulum; Endoplasmic Reticulum Stress; Genetic screening; Genomics; Humans; Life Sciences; Lipid peroxidation; Lipids; Mutation; prodrugs; Proteasomes; Protein folding; Quality control; Short Chain Dehydrogenase-Reductases; short-chain dehydrogenase/reductase; Ubiquitin; ubiquitin-proteasome system; Unfolded Protein Response
• ISSN: 2050-084X; 2050-084X
• DOI: 10.7554/eLife.73913

Hundreds of cytotoxic natural or synthetic lipidic compounds contain chiral alkynylcarbinol motifs, but the mechanism of action of those potential therapeutic agents remains unknown. Using a genetic screen in haploid human cells, we discovered that the enantiospecific cytotoxicity of numerous terminal alkynylcarbinols, including the highly cytotoxic dialkynylcarbinols, involves a bioactivation by HSD17B11, a short-chain dehydrogenase/reductase (SDR) known to oxidize the C-17 carbinol center of androstan-3-alpha,17-beta-diol to the corresponding ketone. A similar oxidation of dialkynylcarbinols generates dialkynylketones, that we characterize as highly protein-reactive electrophiles. We established that, once bioactivated in cells, the dialkynylcarbinols covalently modify several proteins involved in protein-quality control mechanisms, resulting in their lipoxidation on cysteines and lysines through addition. For some proteins, this triggers their association to cellular membranes and results in endoplasmic reticulum stress, unfolded protein response activation, ubiquitin-proteasome system inhibition and cell death by apoptosis. Finally, as a proof-of-concept, we show that generic lipidic alkynylcarbinols can be devised to be bioactivated by other SDRs, including human RDH11 and HPGD/15-PGDH. Given that the SDR superfamily is one of the largest and most ubiquitous, this unique cytotoxic mechanism-of-action could be widely exploited to treat diseases, in particular cancer, through the design of tailored prodrugs.